HDAC9 and cancer: These data provide insight into the mechanism of action of the FDA-approved HDACi, SAHA, which has led us to identify HDAC9, eIF3G and eIF3H as new targets for therapeutic development in hepatocellular carcinoma and possibly other cancers.